Once-Daily Regimen Of Dolutegravir Plus Lamivudine May Suppress HIV Viral Load In People New To Treatment For Up To A Year, Study Suggests.

Medscape (7/30, Boerner, Subscription Publication) reports, “A once-a-day regimen of dolutegravir (Tivicay, GlaxoSmithKline) plus lamivudine suppresses HIV viral load in people new to treatment for up to a year,” researchers concluded. At the Internation...